Meeting
2024 ASCO Annual Meeting
Cost analysis of targeted and immunotherapies in operable esophageal and non-small cell lung cancers.
Authors
Yahya Alwatari
Mayo Clinic, Division of General Thoracic Surgery, Rochester, MN
Yahya Alwatari , Mohamed Shanshal , Nate C Johnson , Viengneesee Thao , Bijan J. Borah , Robert Shen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 8051)
DOI
10.1200/JCO.2024.42.16_suppl.8051
Abstract #
8051
Poster Bd #
313
Abstract Disclosures
Similar Posters
First Author: Jeddeo Paul
Poster
2024 ASCO Annual Meeting
Comparing rates of immune checkpoint inhibitor toxicity in different treatment settings (neoadjuvant, adjuvant, and palliative) in non-small cell lung cancer (NSCLC): A meta-analysis of phase III clinical trials.
First Author: Carolyn Moloney
Poster
2023 ASCO Quality Care Symposium
Tailored doses, tailored savings: Optimizing dosing strategies of immune checkpoint inhibitors.
First Author: Aakash Desai
Poster
2022 ASCO Quality Care Symposium
Estimating prevalence and financial impact of “bagging” oncology drugs: Evidence from privately-insured patients with cancer.
First Author: Ya-Chen Tina Shih